Tricyclic compounds for the treatment of inflammatory disorders

US8981131B2 · kind B2 · utility

Assignee

• PIRAMAL ENTERPRISES LIMITED · IN

Inventors

• Dilip Narayanrao Bhedi · Mumbai, IN
• Ram Vishwakarma · Jammu, IN
• Vaishali Deka · Mumbai, IN
• Dattatray Maruti More · Pune, IN
• Manivannan Ramalingam · Poonamallee, IN
• Ashish Suthar · Jamkhed, IN
• Roda Dalal · Mumbai, IN
• Sapna Parikh · Mumbai, IN
• Aditi Amol Tannu · Mumbai, IN

Key dates

• Filing date: Jul 25, 2008
• Grant date: Mar 17, 2015
• Expiry date: Jun 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H17/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds represented by formula I:wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-α and/or interleukins (IL-1β, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula 1 and pharmaceutical compositions containing them.